Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) AI Stock Analysis

2 Followers

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

(HKEX:8189)

Select Model

Rating:39Underperform

Price Target:HKD 0.11▼(-5.88% Downside)

Action:reiterated

Date:11/11/26

The score is driven primarily by severe financial weaknesses, including persistent losses, high leverage, shrinking equity, and ongoing cash burn. Technical conditions are weak despite oversold readings, and the negative P/E with no dividend provides no valuation support.

Positive Factors

Revenue reboundThe sharp 2025 revenue rebound shows that the company can restore top-line activity after weaker periods. If maintained, stronger sales would provide a larger base from which to improve operating leverage, support product investment, and rebuild financial capacity over the next several quarters.

Negative Factors

Persistent unprofitabilityThe revenue recovery has not translated into sustainable profitability. Continuing operating losses and a materially wider net loss indicate that incremental sales are not yet producing adequate earnings, limiting internal funding capacity and weakening the durability of the company’s financial model.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 253.93M
Dividend Yield: ―
Average Volume (3M): 1.05M
Price to Earnings (P/E): -10.3
Beta (1Y): 0.24
Revenue Growth: 53.32%
EPS Growth: -122.35%
Country: Hong Kong
Employees: 273
Sector: Basic Materials
Sector Strength: 61
Industry: Agricultural Inputs

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound...

How the Company Makes Money

The company primarily makes money by selling its pharmaceutical and/or medical-related products to customers (e.g., hospitals, pharmacies, distributors, or other healthcare institutions), generating revenue from product sales. Additional revenue stre...

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview

Summary

The minimum score reflects structurally weak finances: persistent operating and net losses, sharply reduced shareholders’ equity, high debt relative to equity, and sustained negative operating and free cash flow. Revenue growth is a limited positive, but does not offset the company’s financial risk.

Income Statement

24Negative

Balance Sheet

16Very Negative

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	881.37M	509.43M	385.48M	398.00M	403.73M	476.38M
Gross Profit	70.68M	34.75M	16.97M	21.37M	14.82M	45.60M
EBITDA	-8.26M	-14.08M	-22.11M	4.79M	-2.26M	-29.86M
Net Income	-109.96M	-88.47M	-27.80M	-20.16M	-27.45M	-42.26M
Balance Sheet
Total Assets	443.76M	264.96M	332.53M	303.28M	337.20M	347.60M
Cash, Cash Equivalents and Short-Term Investments	65.29M	29.22M	25.40M	5.93M	9.55M	29.78M
Total Debt	108.79M	109.79M	159.92M	83.56M	102.61M	90.34M
Total Liabilities	414.97M	262.22M	304.09M	238.70M	256.05M	237.24M
Stockholders Equity	22.43M	12.23M	22.15M	49.95M	70.11M	100.78M
Cash Flow
Free Cash Flow	106.08M	-62.84M	-28.83M	-15.62M	-21.62M	-40.38M
Operating Cash Flow	119.16M	-54.58M	-26.27M	-13.15M	-12.82M	-6.68M
Investing Cash Flow	34.56M	31.36M	-37.24M	-467.44K	-12.93M	-8.51M
Financing Cash Flow	-75.01M	27.03M	82.95M	12.73M	6.17M	28.10M

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis

Technical Analysis SentimentNegative

Last Price0.12

Price Trends

50DMA0.21Negative

100DMA0.19Negative

200DMA0.23Negative

Market Momentum

MACD-0.03Positive

RSI21.98Positive

STOCH17.16Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.21, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 21.98 is Positive, neither overbought nor oversold. The STOCH value of 17.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8189.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

HK:8189 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
HK:2198	54Neutral	HKD 3.91B	4.12	13.63%	4.75%	0.90%	16.54%
HK:0301	42Neutral	HKD 3.78B	-200.56	-8.09%	―	3.15%	50.74%
HK:2112	40Underperform	HKD 37.50M	-0.17	14.68%	―	-45.65%	29.13%
HK:8189	39Underperform	HKD 260.34M	-10.32	-634.56%	―	53.32%	-122.35%

* Basic Materials Sector Average

Performance Comparison

HK:8189 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:8189	Tianjin TEDA Biomedical Engineering Co. Ltd. Class H	0.12	-0.27	-69.09%
HK:2112	Grace Life-tech Holdings Limited	0.03	-0.04	-59.68%
HK:2198	China Sanjiang Fine Chemicals Co., Ltd.	3.15	0.35	12.60%
HK:0301	SANVO Fine Chemicals Group Limited	7.93	6.42	425.17%
HK:0660	Wai Chun Bio-Technology Ltd.	0.43	0.23	119.39%
HK:2565	PegBio Co., Ltd. Class H	3.38	-59.88	-94.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H AI Stock Analysis